1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Title

Showing 1,267 results.

Thumbnail for Updated Incidence Trends in Myelodysplastic Syndrome: An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database

MDS - 1422

Updated Incidence Trends in Myelodysplastic Syndrome: An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database

Michael Asare

Poster Presenter: Michael Asare

Thumbnail for Updated Overall Survival (OS) and Long-Term Transfusion Independence (TI) From the Phase 3 COMMANDS Trial in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS)

MDS - 113

Updated Overall Survival (OS) and Long-Term Transfusion Independence (TI) From the Phase 3 COMMANDS Trial in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Guillermo Garcia-Manero

Poster Presenter: Guillermo Garcia-Manero

MDS - 838

Updated Phase 2 Results of Elritercept in Patients With Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms

Rami Komrokji

Poster Presenter: Rami Komrokji

$Thumbnail for Updated Results from Randomized Phase II Dose Optimization Study of Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)$

MM - 1831

Updated Results from Randomized Phase II Dose Optimization Study of Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)

Nisha Joseph

Poster Presenter: Nisha Joseph

$Thumbnail for Updated Results From the Phase 2 IZALCO Study: Efficacy and Safety of Isatuximab Subcutaneous Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma$

MM - 780

Updated Results From the Phase 2 IZALCO Study: Efficacy and Safety of Isatuximab Subcutaneous Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Wanda Vila-Carriles

Poster Presenter: Wanda Vila-Carriles

Thumbnail for Updated Results From the Phase 3 ECHO Trial of Bendamustine-Rituximab With or Without Acalabrutinib in Patients With Previously Untreated Mantle Cell Lymphoma: 50 Months of Follow-up

MCL - 575

Updated Results From the Phase 3 ECHO Trial of Bendamustine-Rituximab With or Without Acalabrutinib in Patients With Previously Untreated Mantle Cell Lymphoma: 50 Months of Follow-up

Michael Wang

Poster Presenter: Michael Wang

Thumbnail for Updated Results of POLARIS-1 (Part 1), a Global Registrational Phase 3 Study: Olverembatinib Combined With Low-Intensity Chemotherapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

ALL - 597

Updated Results of POLARIS-1 (Part 1), a Global Registrational Phase 3 Study: Olverembatinib Combined With Low-Intensity Chemotherapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Suning Chen

Poster Presenter: Suning Chen

$Thumbnail for Updated Safety of Isatuximab Subcutaneous At-Home Administration by On-Body Injector in Relapsed/Refractory Multiple Myeloma in the Phase 3 IRAKLIA Study$

MM - 609

Updated Safety of Isatuximab Subcutaneous At-Home Administration by On-Body Injector in Relapsed/Refractory Multiple Myeloma in the Phase 3 IRAKLIA Study

Sloan Smith

Poster Presenter: Sloan Smith

Thumbnail for Upfront Allogeneic Stem Cell Transplantation With Individualized Venetoclax-Based Conditioning in MECOM-Rearranged Acute Myeloid Leukemia: A Single-Center Retrospective Study

AML - 783

Upfront Allogeneic Stem Cell Transplantation With Individualized Venetoclax-Based Conditioning in MECOM-Rearranged Acute Myeloid Leukemia: A Single-Center Retrospective Study

Milda Mikalonyt?

Poster Presenter: Milda Mikalonyt?